Medikinet Xl

Methylphenidate Hydrochloride, the active ingredient in Medikinet XL, is a central nervous system stimulant presented as an extended‑release tablet for oral use. It is indicated for the management of attention deficit hyperactivity disorder and narcolepsy, helping improve focus, impulse control and wakefulness in children, adolescents and adults.

GNH USA supplies Medikinet XL as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved products to meet global healthcare needs.

Medikinet XL, a central nervous system stimulant, is used in conditions related to attention regulation and excessive daytime sleepiness.

Attention deficit hyperactivity disorder (children and adolescents): improves focus, reduces hyperactivity and impulsivity. Attention deficit hyperactivity disorder (adults): enhances attention and reduces distractibility. Narcolepsy: decreases daytime sleepiness and reduces frequency of sleep attacks.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate head pain. - Stomach pain: abdominal discomfort or cramps.

Serious or Rare Side Effects: - Cardiovascular events: elevated blood pressure or rapid heart rate. - Psychotic symptoms: hallucinations or delusional thinking. - Severe allergic reactions: rash, swelling, or difficulty breathing.

Before initiating therapy, consider the following precautions: - Cardiovascular assessment: evaluate blood pressure and heart rate. - Growth monitoring: regularly check height and weight in children. - Hypersensitivity: avoid use in patients with known allergy to methylphenidate. - Psychiatric history: use caution in individuals with mood disorders or psychosis. - Store at ambient temperature: keep in the original pack, protect from moisture.

Methylphenidate may interact with several drug classes. Review patient medication lists carefully.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other central nervous system stimulants: increased stimulant effects. - Certain antidepressants (e.g., tricyclics): heightened cardiovascular side effects.

Moderate Interactions (Monitor Closely):\n- Antihypertensive agents: possible reduction in blood pressure control. - Antipsychotics: may diminish therapeutic response of methylphenidate. - Seizure threshold‑lowering drugs: increased risk of seizures.